 |
Corporate News
28-Feb-25
|
|
|
|
|
|
|
|
|
|
|
|
Biocon launches GLP-1 peptide, Liraglutide in the UK
|
|
|
|
|
|
|
|
Biocon announced the launch of its GLP-1 peptide, Liraglutide, for diabetes and obesity, in the United Kingdom (U.K.). The drug-device combination will be marketed in the U.K. under the brand names Liraglutide Biocon for diabetes (gVictoza®) and Biolide for chronic weight management (gSaxenda®).
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., earlier this year, making Biocon the first generics company to obtain approval for gLiraglutide in a major regulated market.
|
|
|
|
Previous News |
Biocon Ltd spurts 1.07%, gains for fifth straight session
(
Hot Pursuit
-
03-Jul-25
13:00
)
|
|
|
Nifty above 25,550 mark; oil & gas shares jump
(
Market Commentary
-
Mid-Session
03-Jul-25
10:39
)
|
|
|
Biocon's biologics arm gets regulatory approval in EU for Denosumab biosimilars
(
Hot Pursuit
-
03-Jul-25
09:50
)
|
|
|
Biocon Biologics receives EU marketing authorisation for Vevzuo® and Evfraxy® biosimilars of Denosumab
(
Corporate News
-
03-Jul-25
09:12
)
|
|
|
Biocon's biologics arm gets Health Canada approval for aflibercept biosimilar 'Yesafili'
(
Hot Pursuit
-
27-Jun-25
12:18
)
|
|
|
Biocon raises Rs 4,500 crore via QIP
(
Hot Pursuit
-
21-Jun-25
09:13
)
|
|
|
Restaurant Brands Asia Ltd leads gainers in 'A' group
(
Hot Pursuit
-
19-Jun-25
12:00
)
|
|
|
Biocon get facilities rated
(
Corporate News
-
18-Jun-25
09:41
)
|
|
|
Indices drift lower in early trade; breadth positive
(
Market Commentary
-
Mid-Session
17-Jun-25
09:37
)
|
|
|
Biocon Ltd soars 3.52%, Gains for third straight session
(
Hot Pursuit
-
11-Jun-25
13:05
)
|
|
|
Biocon gets CDSCO approval for Liraglutide drug substance
(
Hot Pursuit
-
03-Jun-25
08:23
)
|
|
|
|
|
|
Other Stories |
|
|
|
|
|
|
|
|
|
|
|
|
|